Diana Ernst, RPh

Editorial Director https://www.empr.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Diabetes

Farxiga Gets FDA Approval for Reducing Heart Failure Hospitalization Risk

Diana Ernst, RPh

October 22, 2019

Farxiga has been approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.

Urinary Tract Infections (UTI)

FDA Panel Votes on Novel Antibiotic for Complicated UTI

Diana Ernst, RPh

October 18, 2019

The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval of cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.

Next post in Urinary Tract Infections (UTI)

Diana Ernst, RPh

All articles by Diana Ernst, RPh

Farxiga Gets FDA Approval for Reducing Heart Failure Hospitalization Risk

FDA Panel Votes on Novel Antibiotic for Complicated UTI

Comparison of Antibiotic Activity in Complicated UTI From Gram-Negative Bacteria